HC Wainwright Issues Optimistic Outlook for Vericel Earnings

Vericel Corporation (NASDAQ:VCEL) – Equities research analysts at HC Wainwright increased their Q4 2026 earnings estimates for Vericel in a research note issued on Friday, February 27th. HC Wainwright analyst S. Ramakanth now forecasts that the biotechnology company will post earnings per share of $0.43 for the quarter, up from their previous estimate of $0.40. HC Wainwright currently has a “Buy” rating and a $64.00 price objective on the stock. The consensus estimate for Vericel’s current full-year earnings is $0.14 per share. HC Wainwright also issued estimates for Vericel’s FY2030 earnings at $2.09 EPS.

Vericel (NASDAQ:VCEL) last released its earnings results on Thursday, February 26th. The biotechnology company reported $0.45 EPS for the quarter, meeting the consensus estimate of $0.45. The company had revenue of $92.92 million for the quarter, compared to analyst estimates of $92.66 million. Vericel had a net margin of 5.98% and a return on equity of 5.17%. The firm’s quarterly revenue was up 23.3% compared to the same quarter last year. During the same quarter last year, the firm earned $0.38 EPS.

Several other equities research analysts have also recently weighed in on the company. Zacks Research cut Vericel from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 12th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Vericel in a research report on Monday, December 29th. Wall Street Zen upgraded shares of Vericel from a “hold” rating to a “buy” rating in a report on Sunday, January 25th. Finally, Truist Financial decreased their target price on shares of Vericel from $50.00 to $45.00 and set a “buy” rating on the stock in a research note on Thursday, December 18th. Four research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $58.50.

Vericel Trading Down 2.7%

Shares of NASDAQ:VCEL opened at $34.39 on Monday. The stock has a market capitalization of $1.75 billion, a P/E ratio of 110.94 and a beta of 1.22. The stock’s 50-day moving average price is $37.01 and its 200-day moving average price is $36.10. Vericel has a 12-month low of $29.24 and a 12-month high of $52.06.

Institutional Trading of Vericel

A number of institutional investors and hedge funds have recently added to or reduced their stakes in VCEL. Huntington National Bank raised its holdings in shares of Vericel by 51.3% in the third quarter. Huntington National Bank now owns 805 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 273 shares in the last quarter. Kestra Advisory Services LLC purchased a new position in Vericel during the 4th quarter valued at about $27,000. Abich Financial Wealth Management LLC purchased a new position in Vericel during the 3rd quarter valued at about $31,000. Quarry LP bought a new stake in shares of Vericel in the 4th quarter valued at about $31,000. Finally, Farther Finance Advisors LLC lifted its position in shares of Vericel by 116.5% in the 4th quarter. Farther Finance Advisors LLC now owns 970 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 522 shares during the period.

About Vericel

Vericel Corporation is a biotechnology company specializing in the development, manufacturing and commercialization of cell-based therapies for patients with severe diseases and conditions. The company’s expertise lies in regenerative medicine, where it harnesses the power of autologous cell processing to create products designed to restore function and promote healing in damaged tissues.

Vericel currently markets two FDA-approved therapies. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is indicated for the repair of symptomatic cartilage defects of the knee in adult patients.